See more : Anhui Xinli Finance Co., Ltd. (600318.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Odonate Therapeutics, Inc. (ODT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Odonate Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Transcontinental Realty Investors, Inc. (TCI) Income Statement Analysis – Financial Results
- Northrop Grumman Corporation (0K92.L) Income Statement Analysis – Financial Results
- LifeStance Health Group, Inc. (LFST) Income Statement Analysis – Financial Results
- China Master Logistics Co., Ltd. (603967.SS) Income Statement Analysis – Financial Results
- Venture Minerals Limited (VTMLF) Income Statement Analysis – Financial Results
Odonate Therapeutics, Inc. (ODT)
About Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 117.04M | 104.03M | 79.95M | 27.90M | 2.62M | 0.00 |
| General & Administrative | 10.39M | 10.90M | 10.82M | 4.84M | 463.00K | 158.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.39M | 10.90M | 10.82M | 4.84M | 463.00K | 158.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -316.00K |
| Operating Expenses | 127.43M | 114.93M | 90.76M | 32.74M | 3.09M | -158.00K |
| Cost & Expenses | 127.43M | 114.93M | 90.76M | 32.74M | 3.09M | 158.00K |
| Interest Income | 0.00 | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 445.00K | 381.00K | 350.00K | 20.00K | 22.82K | 0.00 |
| EBITDA | -125.91M | -111.44M | -88.61M | -32.72M | -3.09M | -158.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -127.43M | -114.93M | -90.76M | -32.74M | -3.09M | -158.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.08M | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -126.35M | -111.83M | -88.96M | -32.74M | -3.09M | -158.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.08M | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Net Income | -126.35M | -111.83M | -88.96M | -32.74M | -3.09M | -158.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.85 | -4.05 | -3.64 | -2.31 | -0.11 | -0.01 |
| EPS Diluted | -3.85 | -4.05 | -3.64 | -2.31 | -0.11 | -0.01 |
| Weighted Avg Shares Out | 32.82M | 27.63M | 24.46M | 14.17M | 26.89M | 26.89M |
| Weighted Avg Shares Out (Dil) | 32.82M | 27.63M | 24.46M | 14.17M | 26.89M | 26.89M |
Odonate Therapeutics (NASDAQ:ODT) Issues Quarterly Earnings Results
Odonate Therapeutics (NASDAQ:ODT) announced its quarterly earnings results on Thursday. The company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.11, Bloomberg Earnings reports. ODT traded down $0.55 during trading hours on...
Here's what the best stock-picking hedge funds are buying
CNBC Pro used Symmetric.io, a hedge-fund tracking firm, to find the best under-the-radar managers and which stocks they recently bought.
Odonate Therapeutics Inc (NASDAQ:ODT) Expected to Announce Earnings of -$1.08 Per Share
Wall Street analysts expect Odonate Therapeutics Inc (NASDAQ:ODT) to report earnings per share of ($1.08) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Odonate Therapeutics’ earnings. The highest EPS estimate is ($1.01) and the...
Odonate Therapeutics (NASDAQ:ODT) Downgraded by BidaskClub
BidaskClub cut shares of Odonate Therapeutics (NASDAQ:ODT) from a buy rating to a hold rating in a report released on Friday, BidAskClub reports. Other equities analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares...
Catorce años de cárcel para el «payaso justiciero» que robaba en locales de Telepizza
Un atracador reincidente acusado de robar hasta en tres ocasiones en el Telepizza de Entrevías en menos de diez días y en una pastelería de la misma zona de Puente de Vallecas ha logrado en el juicio una rebaja de...
Odonate Therapeutics (NASDAQ:ODT) Lifted to "Buy" at BidaskClub
BidaskClub upgraded shares of Odonate Therapeutics (NASDAQ:ODT) from a hold rating to a buy rating in a report issued on Friday, BidAskClub reports. Several other research firms have also issued reports on ODT. Zacks Investment Research lowered Odonate Therapeutics from...
Odonate Therapeutics Inc (NASDAQ:ODT) Receives Average Recommendation of "Hold" from Brokerages
Shares of Odonate Therapeutics Inc (NASDAQ:ODT) have been assigned an average rating of “Hold” from the five brokerages that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has assigned...
Research Analysts' Upgrades for February, 7th (ALNY, AMAT, ASTE, AUPH, AVAV, BJRI, CDNA, CLVS, CYTK, EBIX)
Research Analysts’ upgrades for Friday, February 7th: Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by analysts at BidaskClub from a buy rating to a strong-buy rating. Applied Materials (NASDAQ:AMAT) was upgraded by analysts at BidaskClub from a hold rating to a buy...
Brokerages Anticipate Odonate Therapeutics Inc (NASDAQ:ODT) Will Announce Earnings of -$1.08 Per Share
Equities research analysts predict that Odonate Therapeutics Inc (NASDAQ:ODT) will announce ($1.08) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Odonate Therapeutics’ earnings. The lowest EPS estimate is ($1.14) and...
Estos jugadores de LaLiga Genuine Santander también forman parte de Telepizza
Fundación LaLiga y Grupo Telepizza han llegado a un acuerdo para integrar a los jugadores con discapacidad en los equipos de trabajo de la compañía
Source: https://incomestatements.info
Category: Stock Reports